Of the strong candidates for GUV’s Deal of the Year, Lund and Edinburgh universities-founded drug developer Galecto Biotech sealed the award for a €79m ($90m) series C close that supplemented a promising set of clinical data for its lead candidate.

Stanford-backed medical supplies delivery service Zipline has revealed two funding rounds totaling $190m, one of which is a $70m series C that included existing backer GV.

Quell Therapeutics will develop treatments for conditions such as solid organ transplant rejection and has also secured capital from UCL Technology Fund.

The series A, led by corporate venturing unit GV, may not have been last week’s largest deal, but Verve’s tie-up with fellow Harvard spinout Beam Therapeutics tells an intriguing story.

OUP and Sofinnova Partners invested in 28-7 Therapeutics to take its series A round to $82.8m, enabling the Harvard spinout to pursue accelerated development of its cancer drug pipeline.

GV led a $58.5m round for the heart disease drug developer, which is advancing research conducted at Harvard University and Broad Institute and has a partnership in place with Harvard spinout Beam Therapeutics.

UCL spinout Promethera Biosciences has increased its series D round to $44.4m with a $33.1m Mitsui and Medipal-backed extension, adding to Itochu’s initial investment earlier this year.

More than six years after being launched by Open University to offer massive open online courses, FutureLearn has raised its first external funding from Seek Group.

Osage University Partners has participated in a $62m series B round for Satsuma Pharmaceuticals, which also featured Shin Nippon Biomedical Laboratories.

Osage University has returned for a $75m series B round raised by Arrakis Therapeutics, which has licensed technology from University of Pennsylvania.